More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$44.71B
EPS
13.59
P/E ratio
41.4
Price to sales
10
Dividend yield
--
Beta
1.552935
Previous close
$563.53
Today's open
$555.96
Day's range
$552.25 - $571.88
52 week range
$504.56 - $769.98
show more
CEO
Jonathan J. Mazelsky
Employees
11000
Headquarters
Westbrook, ME
Exchange
Nasdaq Global Select
Shares outstanding
78882997
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
Baron Asset Fund Q1 2026 Contributors, Detractors And Recent Activity
SpaceX is generating significant value with the rapid expansion of its Starlink broadband service. CoStar Group's shares fell due to multiple compression driven by rising fears about the potential impact of AI on the company's business.
Seeking Alpha • Jun 1, 2026

IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference
IDEXX Laboratories NASDAQ: IDXX President and CEO Michael Erickson used a Stifel investor conference appearance to emphasize the company's innovation pipeline, expanding commercial reach and growing use of software and artificial intelligence across veterinary diagnostics.
MarketBeat • May 30, 2026

IDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcript
IDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Seeking Alpha • May 27, 2026

IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Fecal Dx™ antigen testing with taeniid tapeworm detection for broader intestinal parasite screening in wellness and sick-pet care.
Business Wire • May 26, 2026

IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX integrates SDMA into most common Catalyst chemistry profiles, enabling earlier detection of kidney disease through routine in‑clinic testing.
Business Wire • May 19, 2026

IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 27, 2026 from 10:55 am – 11:25 am (ET). A live audio webcast of the presentation will be available through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the presentation will b.
Business Wire • May 14, 2026

Idexx Laboratories Raises Guidance On Higher Clinical Visits, Diagnostic Frequency
Idexx Laboratories Inc (NASDAQ:IDXX) shares are up on Tuesday as the company recently announced strong first-quarter results, showcasing a 14% revenue growth.
Benzinga • May 5, 2026

Idexx Claws Down A Beat As Shares Bound Higher On A Guidance Hike
Idexx stock jumped early Tuesday on better-than-expected first-quarter sales and earnings. The firm raised its 2026 guidance.
Investors Business Daily • May 5, 2026

IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
Seeking Alpha • May 5, 2026

IDEXX Laboratories Announces First Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $1,141 million for the first quarter of 2026, an increase of 14% as reported and 11% organic, driven by Companion Animal Group ("CAG") growth of 15% as reported and 12% organic. First quarter earnings per diluted share (“EPS”) were $3.47, an increase of 17% as reported and 15% on a c.
Business Wire • May 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell IDEXX Laboratories Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.